CAM
ENTA icon

Capstone Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Capstone Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$212K Buy
+5,890
New +$188K 0.01% 1485
2017
Q1 		– Sell
-6,390
Closed -$214K – 1614
2016
Q4 		$214K Buy
+6,390
New +$183K 0.01% 1530

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Capstone Asset Management's ENTA Position: Q2 2017 in Review

Capstone Asset Management opened a new position in Enanta Pharmaceuticals (ENTA) in Q2 2017: 5,890 shares worth $212K. The stake represents 0.01% of the portfolio and ranks #1485 among its holdings. This is a return to the name: Capstone Asset Management previously reported a position in ENTA as recently as Q4 2016.

Capstone Asset Management first reported a position in ENTA in Q4 2016 and has held it in 2 quarters since. The position peaked at $214K in Q4 2016. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2017.

  • Capstone Asset Management held 5,890 shares of Enanta Pharmaceuticals worth $212K as of Q2 2017.
  • Enanta Pharmaceuticals was a new Capstone Asset Management position in Q2 2017.
  • Enanta Pharmaceuticals made up 0.01% of Capstone Asset Management's portfolio in Q2 2017, its #1485 holding.
  • Capstone Asset Management first reported a position in Enanta Pharmaceuticals in Q4 2016 and has held it in 2 quarters since.
  • Capstone Asset Management's Enanta Pharmaceuticals position peaked at $214K in Q4 2016.
  • 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.